FDA Approval - Growth Hormone Peptides
In 2010, the FDA approved a growth-hormone peptide called Tesamorelin.
It's a synthetic GHRH analog — same physiological pathway as CJC-1295, same family as Ipamorelin and Sermorelin.
To this day, it's the only growth-axis peptide approved for any indication.
That's strange when you think about it.
The growth-axis peptide category is one of the most studied in the field.
CJC-1295 has been in research use since the 1990s.
Ipamorelin since around the same time.
Sermorelin even longer.
So why did one specific molecule make it through, and the rest didn't?
The answer is simple, and it's not about science.
Why Tesamorelin cleared
Tesamorelin had a commercial sponsor: Theratechnologies.
They picked a defined indication — HIV-associated lipodystrophy — ran the Phase 2 and Phase 3 trials, and pushed it through the standard NDA pathway.
That pathway costs roughly $1 billion to $2 billion.
To justify that kind of spend, a sponsor needs a clear patent window and a clear revenue path.
Tesamorelin had both.
Why Ipamorelin didn't
Ipamorelin is a ghrelin-receptor agonist.
It's been in research use for 30 years and has a substantial body of academic literature.
There's no defined indication keeping it from approval — there's just no commercial sponsor.
Same story for CJC-1295. Same for Sermorelin (well, almost — Sermorelin briefly had a brand version called Geref that came and went).
Same for most of the peptides researchers actually want to study.
The molecule isn't the gating factor.
The economics are.
This is the part of the system most people don't talk about: the FDA pipeline doesn't decide what's worth approving based on biology.
It decides based on who's willing to pay the freight.
Drugs that don't promise hundreds of millions in returns don't get developed — no matter how strong the underlying science is.
The pipeline runs on profit, not biology, and biology has to wait its turn behind whatever Big Pharma's pockets need lined this quarter.
What this means for the PCAC docket
The 12 peptides headed to PCAC review on July 23 and 24 aren't failed drugs.
They aren't molecules the FDA rejected.
Most of them simply never had a sponsor file an NDA in the first place.
They've been in research use for decades, generating thousands of researcher-logged protocols and observational reports along the way — but never the formal trials that only Big Pharma money can fund.
The PCAC question is narrower than full FDA approval: does each compound qualify for compounding under 503A?
That's a different bar — and a more honest one for molecules whose biology has outpaced their economics.
What this means for you
Tesamorelin is in the APR Metabolic Category. CJC-1295, Ipamorelin, Sermorelin, and IGF1-LR3 are in the APR Growth Category.
Same physiological pathway, different regulatory paths — and the difference between them is mostly an accounting decision made twenty years ago.
The path through the FDA is open. It's just expensive and indication-specific.
Most molecules don't get to use it.
That doesn't make them less worth understanding.
